These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
602 related articles for article (PubMed ID: 32349307)
1. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors. Al-Warhi T; El Kerdawy AM; Aljaeed N; Ismael OE; Ayyad RR; Eldehna WM; Abdel-Aziz HA; Al-Ansary GH Molecules; 2020 Apr; 25(9):. PubMed ID: 32349307 [TBL] [Abstract][Full Text] [Related]
2. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806 [TBL] [Abstract][Full Text] [Related]
3. Quinazoline-oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies. Syam YM; Abd El-Karim SS; Abdel-Mohsen HT Arch Pharm (Weinheim); 2024 Oct; 357(10):e2300682. PubMed ID: 38995191 [TBL] [Abstract][Full Text] [Related]
4. Design and Synthesis of New Farghaly TA; Pashameah RA; Bayazeed A; Al-Soliemy AM; Alsaedi AMR; Harras MF Med Chem; 2024; 20(1):63-77. PubMed ID: 37723960 [TBL] [Abstract][Full Text] [Related]
5. Benzimidazole-oxindole hybrids: A novel class of selective dual CDK2 and GSK-3β inhibitors of potent anticancer activity. Abdel-Mohsen HT; Syam YM; Abd El-Ghany MS; Abd El-Karim SS Arch Pharm (Weinheim); 2024 Oct; 357(10):e2300721. PubMed ID: 39041665 [TBL] [Abstract][Full Text] [Related]
6. Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies. Hassan RM; Ali IH; El Kerdawy AM; Abo-Elfadl MT; Ghannam IAY Bioorg Chem; 2024 Nov; 152():107728. PubMed ID: 39178704 [TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
8. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights. Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872 [TBL] [Abstract][Full Text] [Related]
9. Targeting tyrosine kinase: Development of acridone - pyrrole - oxindole hybrids against human breast cancer. Kaur M; Singh P Bioorg Med Chem Lett; 2019 Jan; 29(1):32-35. PubMed ID: 30446310 [TBL] [Abstract][Full Text] [Related]
10. Marine-Inspired Bis-indoles Possessing Antiproliferative Activity against Breast Cancer; Design, Synthesis, and Biological Evaluation. Eldehna WM; Hassan GS; Al-Rashood ST; Alkahtani HM; A Almehizia A; Al-Ansary GH Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32252280 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. Chen G; Weng Q; Fu L; Wang Z; Yu P; Liu Z; Li X; Zhang H; Liang G Bioorg Med Chem; 2014 Dec; 22(24):6953-60. PubMed ID: 25456085 [TBL] [Abstract][Full Text] [Related]
13. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models. Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs). Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628 [TBL] [Abstract][Full Text] [Related]
15. New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization. Ezelarab HAA; Ali TFS; Abbas SH; Sayed AM; Beshr EAM; Hassan HA Mol Divers; 2024 Apr; 28(2):563-580. PubMed ID: 36790582 [TBL] [Abstract][Full Text] [Related]
16. Novel 2-[thio]acetamide linked quinazoline/1,2,4-triazole/chalcone hybrids: Design, synthesis, and anticancer activity as EGFR inhibitors and apoptotic inducers. Abdelkhalek AS; Kothayer H; Soltan MK; Ibrahim SM; Elbaramawi SS Arch Pharm (Weinheim); 2024 Jul; 357(7):e2300627. PubMed ID: 38593298 [TBL] [Abstract][Full Text] [Related]
17. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents. Eldehna WM; Abo-Ashour MF; Nocentini A; El-Haggar RS; Bua S; Bonardi A; Al-Rashood ST; Hassan GS; Gratteri P; Abdel-Aziz HA; Supuran CT Eur J Med Chem; 2019 Jan; 162():147-160. PubMed ID: 30445264 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and SARs study of novel spiro-oxindoles as potent antiproliferative agents with CDK-2 inhibitory activities. Al-Jassas RM; Islam MS; Al-Majid AM; Nafie MS; Haukka M; Rahman AFMM; Alayyaf AMA; Barakat A Arch Pharm (Weinheim); 2023 Aug; 356(8):e2300185. PubMed ID: 37253118 [TBL] [Abstract][Full Text] [Related]
20. Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations. Eldehna WM; El Hassab MA; Abo-Ashour MF; Al-Warhi T; Elaasser MM; Safwat NA; Suliman H; Ahmed MF; Al-Rashood ST; Abdel-Aziz HA; El-Haggar R Bioorg Chem; 2021 May; 110():104748. PubMed ID: 33684714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]